Clinical Trial Update: Real World Utilization and Outcomes With Dacomitinib First Line Treatment for EGFR Mutation-positive Advanced Non Small Cell Lung Cancer Among Asian Patients - A Multi Center Chart Review

View source ↗

Summary

This update reports real-world utilization and outcomes of first-line dacomitinib for EGFR-mutant advanced non-small cell lung cancer among Asian patients in a …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Dacomitinib (dacomitinib)

Snippet

Sponsor: Pfizer | Conditions: Lung Cancer | Status: COMPLETED | Results posted: 2025-05-31